

## The European Patent Office intend to grant Brighter's patent for AI-powered monitoring of medical devices.

The European Patent Office intend to grant Brighter's European patent application 16744322.5 regarding Artificial Intelligence-driven medical device monitoring functionality.

The patent secures rights to unique functionalities in The Benefit Loop to secure operations of medical devices. It also adds valuable functionalities to Actiste, Brighter's unique diabetes management service, currently being introduced to the market in the United Arab Emirates, Indonesia, Thailand and Sweden.

– Over the years, Brighter has built an strong IP portfolio, and we are continuously strengthening it even further through continuous development within both current and new upcoming business areas. As part of the company's long-term strategy IP is considered an active asset that strengthens existing business but also enables e.g. licensing, says Truls Sjöstedt, Brighter's CEO and founder.

### **About Brighter**

Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. [www.brighter.se](http://www.brighter.se)

### **About Actiste**

Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.


Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. [www.actiste.com](http://www.actiste.com)

*The Company's shares are listed on [NASDAQOMX First North/BRIG](http://NASDAQOMX First North/BRIG).*

*Visit our website and subscribe to press releases: [www.brighter.se](http://www.brighter.se)*

# Brighter

Follow us on:



[www.introduce.se](http://www.introduce.se)

## Certified Adviser

Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, [info@eminova.se](mailto:info@eminova.se), [www.eminova.se](http://www.eminova.se).

For further information, please contact:

Henrik Norström, COO

Telephone: +46 733 40 30 45

Email: [henrik.norstrom@brighter.se](mailto:henrik.norstrom@brighter.se)

Truls Sjöstedt, CEO

Telephone: +46 709 73 46 00

Email: [truls.sjostedt@brighter.se](mailto:truls.sjostedt@brighter.se)

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CEST on August 8<sup>th</sup>, 2018.